Alterity Therapeutics (ATHE) has an average rating of buy and mean price target of $17.60, according to analysts polled by FactSet.
What else is happening in Research?
Research
Kraken Robotics Initiated at Outperform at RBC
RBC Capital Markets initiated coverage of Kraken Robotics Inc. (PNG.V) with an outperform rating and CA$6 price target.The Canadian marine technology company's acquisition of Covelya Group "transforms Kraken into a full-subsystem undersea technology provider, marking a step-change in scale and customer stickiness," analyst James McGarragle said."Combined with structural defence and commercial tailwinds driving strong growth, we see a compelling path to operating leverage and EBITDA margin expansion through FY28," McGarragle said in a note to clients.
$PNG.V
Research
Kepler Cheuvreux Trims Wizz Air PT, Keeps Hold Rating
Kepler Cheuvreux on Tuesday reduced its price target for European budget airline Wizz Air Holdings (WIZZ.L) to 10.00 pounds sterling from 12.00 pounds, with an unchanged hold rating.
$WIZZ.L
Research
Danske Bank Cuts Rockwool PT, Keeps Buy Rating
Danske Bank on Tuesday lowered its price target for mineral wool products company Rockwool (ROCK-A.CO, ROCK-B.CO) to 226 Danish kroner from 240 kroner, while maintaining its buy rating.
$ROCK-A.CO$ROCK-B.CO